Pricing Log in Create free account

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) vs GT Biopharma, Inc. (GTBP)

Chemomab Therapeutics Ltd. Sponsored ADR and GT Biopharma, Inc. are both Biotechnology companies. Chemomab Therapeutics Ltd. Sponsored ADR and GT Biopharma, Inc. are of similar size ($9.4M and $9.1M). Chemomab Therapeutics Ltd. Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; GT Biopharma, Inc. trades at 0.8×. Across the 10 metrics below, GT Biopharma, Inc. leads on 6 and Chemomab Therapeutics Ltd. Sponsored ADR on 4.

Valuation

Metric CMMB GTBP Biotechnology median
P/E n/m 0.76 10.60
P/S n/m 114.39 9.40
P/B 1.18 1.92 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 475.21 9.02
Earnings yield (62.50%) 130.83% (32.88%)
Free cash flow yield (355.43%) (207.77%) (23.13%)

Profitability

Metric CMMB GTBP Biotechnology median
Gross margin 0.00% 41.67% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (82.17%) 102.03% (51.96%)
Return on assets (70.70%) (176.27%) (46.06%)
Return on invested capital (247.40%) 0.00% 0.00%

Growth

Metric CMMB GTBP Biotechnology median
Revenue growth (TTM) — (76.19%) 6.76%
EPS growth (last fiscal year) 53.65% 3.75% 29.88%
Revenue growth, 5-year CAGR — 19.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CMMB GTBP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.41 2.61 4.97
Net debt to EBITDA 1.09 0.56 1.01

Dividend

Metric CMMB GTBP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CMMB GTBP Biotechnology median
Market cap 9.06m 9.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack